Sun Pharma Advanced Research Company Limited (BOM:532872)
India
· Delayed Price · Currency is INR 159.60
+0.60 (0.38%)
At close: Jun 26, 2025
BOM:532872 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 717.7 | 755.45 | 2,388 | 1,372 | 2,530 | Upgrade
|
| 717.7 | 755.45 | 2,388 | 1,372 | 2,530 | Upgrade
| |
Revenue Growth (YoY) | -5.00% | -68.36% | 73.98% | -45.74% | 229.31% | Upgrade
|
Cost of Revenue | 231.2 | 364.39 | 283.24 | 235.6 | 328.59 | Upgrade
|
Gross Profit | 486.5 | 391.07 | 2,105 | 1,137 | 2,201 | Upgrade
|
Selling, General & Admin | 2,453 | 2,944 | 2,390 | 1,658 | 1,457 | Upgrade
|
Research & Development | 813.3 | 1,014 | 1,495 | 1,084 | 1,840 | Upgrade
|
Other Operating Expenses | 451.6 | 426.59 | 339.19 | 254.38 | 253.45 | Upgrade
|
Operating Expenses | 3,842 | 4,508 | 4,341 | 3,098 | 3,658 | Upgrade
|
Operating Income | -3,355 | -4,117 | -2,236 | -1,961 | -1,457 | Upgrade
|
Interest Expense | -90.4 | -11.75 | -76.35 | -133.29 | -106.5 | Upgrade
|
Interest & Investment Income | - | 254.76 | 75.95 | 14.1 | 8.97 | Upgrade
|
Currency Exchange Gain (Loss) | - | -28.99 | -20.69 | -8.39 | 30.14 | Upgrade
|
Other Non Operating Income (Expenses) | 17.9 | -2.89 | 0.17 | 0.77 | 4.71 | Upgrade
|
EBT Excluding Unusual Items | -3,428 | -3,906 | -2,257 | -2,088 | -1,520 | Upgrade
|
Gain (Loss) on Sale of Investments | - | 31.81 | 32.65 | 4.64 | 5.67 | Upgrade
|
Gain (Loss) on Sale of Assets | - | 5.82 | -1.13 | 48.93 | 2.64 | Upgrade
|
Pretax Income | -3,428 | -3,868 | -2,226 | -2,034 | -1,511 | Upgrade
|
Income Tax Expense | -2.7 | 3.82 | - | - | - | Upgrade
|
Net Income | -3,425 | -3,872 | -2,226 | -2,034 | -1,511 | Upgrade
|
Net Income to Common | -3,425 | -3,872 | -2,226 | -2,034 | -1,511 | Upgrade
|
Shares Outstanding (Basic) | 325 | 325 | 285 | 263 | 262 | Upgrade
|
Shares Outstanding (Diluted) | 325 | 325 | 285 | 263 | 262 | Upgrade
|
Shares Change (YoY) | 0.04% | 13.99% | 8.19% | 0.42% | - | Upgrade
|
EPS (Basic) | -10.55 | -11.93 | -7.82 | -7.73 | -5.77 | Upgrade
|
EPS (Diluted) | -10.55 | -11.93 | -7.82 | -7.73 | -5.77 | Upgrade
|
Free Cash Flow | -3,706 | -4,557 | -845.05 | -2,409 | -1,579 | Upgrade
|
Free Cash Flow Per Share | -11.42 | -14.04 | -2.97 | -9.15 | -6.03 | Upgrade
|
Gross Margin | 67.79% | 51.77% | 88.14% | 82.83% | 87.01% | Upgrade
|
Operating Margin | -467.51% | -544.98% | -93.66% | -142.86% | -57.60% | Upgrade
|
Profit Margin | -477.23% | -512.56% | -93.22% | -148.20% | -59.75% | Upgrade
|
Free Cash Flow Margin | -516.41% | -603.21% | -35.39% | -175.53% | -62.42% | Upgrade
|
EBITDA | -3,231 | -4,023 | -2,149 | -1,877 | -1,366 | Upgrade
|
EBITDA Margin | - | - | -89.99% | -136.79% | -54.01% | Upgrade
|
D&A For EBITDA | 123.9 | 93.69 | 87.74 | 83.25 | 90.88 | Upgrade
|
EBIT | -3,355 | -4,117 | -2,236 | -1,961 | -1,457 | Upgrade
|
EBIT Margin | - | - | -93.66% | -142.86% | -57.60% | Upgrade
|
Revenue as Reported | 735.6 | 1,050 | 2,497 | 1,441 | 2,584 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.